The approval is supported by a randomized trial showing that pembrolizumab nearly doubled progression-free survival compared to the standard chemotherapy regimen.
Some oncologists said 10 mutations/Mb is an acceptable TMB cutoff in patients who are out of options, while others worry it will drive immunotherapy use in those unlikely to have a lasting benefit.
